Hormonal therapy and depression: Are we overlooking an important therapeutic alternative?

Journal of Psychosomatic Research

Volumn 62, Issue 4, 2007, Pages 473-485

  Ancelin, Marie Laure ^a,b   Scali, Jacqueline ^a,b   Ritchie, Karen ^a,b  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Biological vulnerability; Cumulated lifelong exposure to steroids; Depression; Estrogens; Female reproductive cycle; Hormone therapy

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 5ALPHA PREGNANE 3,20 DIONE; ANDROGEN; ANTIDEPRESSANT AGENT; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; DIETHYLSTILBESTROL; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; ESTROGEN; GESTAGEN; GONADORELIN AGONIST; IMIPRAMINE; LEUPRORELIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PREGNANE DERIVATIVE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; STEROID; TAMOXIFEN;

ADJUVANT THERAPY; ANXIETY DISORDER; BREAST CANCER; CHILDBIRTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG DOSE REDUCTION; EATING DISORDER; ENDOCRINE FUNCTION; ENVIRONMENTAL FACTOR; ESTROGEN ACTIVITY; ESTROGEN THERAPY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENITAL MALFORMATION; GYNECOLOGIC DISEASE; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; IRRITABILITY; LIFESPAN; MAJOR DEPRESSION; MEDLINE; MENARCHE; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUATION; MENSTRUATION DISORDER; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; NONHUMAN; OVARIECTOMY; PREDICTION; PREGNANCY; PREMENSTRUAL SYNDROME; PREVALENCE; PROPHYLAXIS; PSYCINFO; PUERPERAL DEPRESSION; PUERPERAL PSYCHOSIS; PUERPERIUM; REPRODUCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS; VASOMOTOR DISORDER;

ADOLESCENT; ADULT; AFFECT; DEPRESSIVE DISORDER; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PERSONALITY ASSESSMENT; PREGNANCY; TREATMENT OUTCOME;

EID: 33947309439     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2006.12.019     Document Type: Review

References (170)

1. Robins L., Helzer J., Weissman M., Orvaschel H., Gruenberg E., Burke J., and Regier D. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41 (1984) 949-958
2. Kessler R., McGonagle K., Swartz M., Blazer D., and Nelson C. Sex and depression in the National Comorbidity Survey: I. Lifetime prevalence, chronicity and recurrence. J Affect Disord 29 (1993) 85-96
3. Ritchie K., Artero S., Beluche I., Ancelin M., Mann A., Dupuy A., Malafosse A., and Boulenger J. Prevalence of DSM-IV psychiatric disorder in the French elderly population. Br J Psychiatry 184 (2004) 147-152
4. Alonso J., Angermeyer M., Bernert S., Bruffaerts R., Brugha T., Bryson H., et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl (2004) 21-27
5. Garcia-Segura L., Azcoitia I., and DonCarlos L. Neuroprotection by estradiol. Prog Neurobiol 63 (2001) 29-60
6. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 3 (2002) 433-442
7. Burt V., and Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 63 (2002) 9-15
8. Kornstein S. The evaluation and management of depression in women across the life span. J Clin Psychiatry 62 (2001) 11-17
9. Noble R. Depression in women. Metabolism 54 (2005) 49-52
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1994), American Psychiatric Association, Washington (DC)
11. Steiner M., Pearlstein T., Cohen L., Endicott J., Kornstein S., Roberts C., Roberts D., and Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 15 (2006) 57-69
12. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 28 (2003) 55-99
13. Bebbington P., Dunn G., Jenkins R., Lewis G., Brugha T., Farrell M., and Meltzer H. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 28 (1998) 9-19
14. Halbreich U., Borenstein J., Pearlstein T., and Kahn L. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder. Psychoneuroendocrinology 28 (2003) 1-23
15. Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 95 (1997) 169-176
16. Rubinow D., Roy-Byrne P., Hoban M., Grover G., Stambler N., and Post R. Premenstrual mood changes. Characteristic patterns in women with and without premenstrual syndrome. J Affect Disord 10 (1986) 85-90
17. Harlow B., Cohen L., Otto M., Spiegelman D., and Cramer D. Early life menstrual characteristics and pregnancy experiences among women with and without major depression: the Harvard study of moods and cycles. J Affect Disord 79 (2004) 167-176
18. Kimmel S., Gonsalves L., Youngs D., and Gidwani G. Fluctuating levels of antidepressants premenstrually. J Psychosom Obstet Gynaecol 13 (1992) 277-280
19. Jensvold M., Reed K., Jarett D., and Hamilton J. Menstrual cycle-related depressive symptoms treated with variable antidepressant dosage. J Womens Health 1 (1992) 109-115
20. Schmidt P., Nieman L., Grover G., Muller K., Merriam G., and Rubinow D. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 324 (1991) 1174-1179
21. Warnock J., and Bundren J. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull 33 (1997) 311-316
22. Brown C., Ling F., Andersen R., Farmer R., and Arheart K. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84 (1994) 779-786
23. Freeman E., Sondheimer S., Rickels K., and Albert J. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. J Clin Psychiatry 54 (1993) 192-195
24. Wyatt K., Dimmock P., Ismail K., Jones P., and O'Brien P. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG 111 (2004) 585-593
25. Schmidt P., Nieman L., Danaceau M., Adams L., and Rubinow D. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338 (1998) 209-216
26. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28 (2003) 139-168
27. Strous R., Maayan R., and Weizman A. The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. Eur Neuropsychopharmacol 16 (2006) 155-169
28. Rapkin A., Morgan M., Goldman L., Brann D., Simone D., and Mahesh V. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 (1997) 709-714
29. Monteleone P., Luisi S., Tonetti A., Bernardi F., Genazzani A., Luisi M., Petraglia F., and Genazzani A. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 142 (2000) 269-273
30. Wang M., Seippel L., Purdy R., and Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 81 (1996) 1076-1082
31. Bicikova M., Dibbelt L., Hill M., Hampl R., and Starka L. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 30 (1998) 227-230
32. Schmidt P., Purdy R., Moore P., Paul S., and Rubinow D. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 79 (1994) 1256-1260
33. Girdler S., Straneva P., Light K., Pedersen C., and Morrow A. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49 (2001) 788-797
34. Freeman E., Frye C., Rickels K., Martin P., and Smith S. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 22 (2002) 516-520
35. Rapkin A., Morgan M., Sogliano C., Biggio G., and Concas A. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril 85 (2006) 1371-1378
36. Eser D., Schule C., Baghai T., Romeo E., Uzunov D., and Rupprecht R. Neuroactive steroids and affective disorders. Pharmacol Biochem Behav (2006)
37. Gilbert S., Evans E., Ross L., Sellers E., Purdy R., and Romach M. 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecol Endocrinol 21 (2005) 268-279
38. Pearson Murphy B., Steinberg S., Hu F., and Allison C. Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5 alpha-dihydroprogesterone in depressed patients during the latter half of pregnancy. J Clin Endocrinol Metab 86 (2001) 5981-5987
39. Brett M., and Baxendale S. Motherhood and memory: a review. Psychoneuroendocrinology 26 (2001) 339-362
40. Pop V., Essed G., de Geus C., van Son M., and Komproe I. Prevalence of postpartum depression-or is it post-puerperium depression?. Acta Obstet Gynecol Scand 72 (1993) 354-358
41. Josefsson A., Berg G., Nordin C., and Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 80 (2001) 251-255
42. Evans J., Heron J., Francomb H., Oke S., and Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 323 (2001) 257-260
43. Kumar R., and Robson K. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 144 (1984) 35-47
44. Watson J., Elliott S., Rugg A., and Brough D. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 144 (1984) 453-462
45. Nappi R., Petraglia F., Luisi S., Polatti F., Farina C., and Genazzani A. Serum allopregnanolone in women with postpartum "blues". Obstet Gynecol 97 (2001) 77-80
46. Yonkers K., Ramin S., Rush A., Navarrete C., Carmody T., March D., Heartwell S., and Leveno K. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry 158 (2001) 1856-1863
47. Hannah P., Adams D., Lee A., Glover V., and Sandler M. Links between early post-partum mood and post-natal depression. Br J Psychiatry 160 (1992) 777-780
48. Lane A., Keville R., Morris M., Kinsella A., Turner M., and Barry S. Postnatal depression and elation among mothers and their partners: prevalence and predictors. Br J Psychiatry 171 (1997) 550-555
49. Cohen L., Altshuler L., Stowe Z., and Faraone S. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment. A preliminary retrospective study. Psychother Psychosom 73 (2004) 255-258
50. Altshuler L., Cohen L., Moline M., Kahn D., Carpenter D., and Docherty J. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med (2001) 1-107
51. Bloch M., Schmidt P., Danaceau M., Murphy J., Nieman L., and Rubinow D. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157 (2000) 924-930
52. Avis N., Brambilla D., McKinlay S., and Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 4 (1994) 214-220
53. Maartens L., Knottnerus J., and Pop V. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 42 (2002) 195-200
54. Harlow B., Wise L., Otto M., Soares C., and Cohen L. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard study of moods and cycles. Arch Gen Psychiatry 60 (2003) 29-36
55. Dennerstein L., Guthrie J., Clark M., Lehert P., and Henderson V. A population-based study of depressed mood in middle-aged, Australian-born women. Menopause 11 (2004) 563-568
56. Freeman E., Sammel M., Liu L., Gracia C., Nelson D., and Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 61 (2004) 62-70
57. Freeman E., Sammel M., Lin H., and Nelson D. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 63 (2006) 375-382
58. Cohen L., Soares C., Vitonis A., Otto M., and Harlow B. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 63 (2006) 385-390
59. Schmidt P., Haq N., and Rubinow D. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 161 (2004) 2238-2244
60. Joffe H., Hall J., Soares C., Hennen J., Reilly C., Carlson K., and Cohen L. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 9 (2002) 392-398
61. Schmidt P., Nieman L., Danaceau M., Tobin M., Roca C., Murphy J., and Rubinow D. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 183 (2000) 414-420
62. Soares C., Almeida O., Joffe H., and Cohen L. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 58 (2001) 529-534
63. Cohen L., Soares C., Poitras J., Prouty J., Alexander A., and Shifren J. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 160 (2003) 1519-1522
64. Harlow B., Cramer D., Annis K., and Xu H. Association of medically treated depression and age at natural menopause. Does "incessant" ovulation increase risk for early menopause?. Am J Epidemiol 141 (1995) 1170-1176
65. Daly R., Danaceau M., Rubinow D., and Schmidt P. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry 160 (2003) 1842-1846
66. Kritz-Silverstein D., Von Muhlen D., Ganiats T., and Barrett-Connor E. Hysterectomy status, estrogen use and quality of life in older women: the Rancho Bernardo Study. Qual Life Res 13 (2004) 55-62
67. Laughlin G., Barrett-Connor E., Kritz-Silverstein D., and Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85 (2000) 645-651
68. Sherwin B., and Gelfand M. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 10 (1985) 325-335
69. Taylor M. Psychological consequences of surgical menopause. J Reprod Med 46 (2001) 317-324
70. Nathorst-Boos J., von Schoultz B., and Carlstrom K. Elective ovarian removal and estrogen replacement therapy-effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 14 (1993) 283-293
71. Ballinger C. Psychiatric morbidity and the menopause: survey of a gynaecological out-patient clinic. Br J Psychiatry 131 (1977) 83-89
72. Carlson K., Miller B., and Fowler F. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 83 (1994) 556-565
73. Gath D., Rose N., Bond A., Day A., Garrod A., and Hodges S. Hysterectomy and psychiatric disorder: are the levels of psychiatric morbidity falling?. Psychol Med 25 (1995) 277-283
74. Ryan M., Dennerstein L., and Pepperell R. Psychological aspects of hysterectomy. A prospective study. Br J Psychiatry 154 (1989) 516-522
75. Duffy L., Greenberg D., Younger J., and Ferraro M. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 40 (1999) 304-338
76. Oinonen K., and Mazmanian D. To what extent do oral contraceptives influence mood and affect?. J Affect Disord 70 (2002) 229-240
77. Wagner K. Major depression and anxiety disorders associated with Norplant. J Clin Psychiatry 57 (1996) 152-157
78. Joffe H., Cohen L., and Harlow B. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 (2003) 1523-1530
79. Smith R., Studd J., Zamblera D., and Holland E. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 102 (1995) 475-484
80. Kroll R., and Rapkin A. Treatment of premenstrual disorders. J Reprod Med 51 (2006) 359-370
81. Wyatt K., Dimmock P., and O'Brien P. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev (2002) CD001396
82. Lawrie T., Herxheimer A., and Dalton K. Oestrogens and progestogens for preventing and treating postnatal depression. Cochrane Database Syst Rev (2000) CD0016
83. Gregoire A., Kumar R., Everitt B., Henderson A., and Studd J. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 347 (1996) 930-933
84. Ahokas A., Kaukoranta J., Wahlbeck K., and Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 62 (2001) 332-336
85. Soares C., Poitras J., and Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging 20 (2003) 85-100
86. Soares C., Joffe H., Cohen L., and Almeida O. Efficacy of 17beta-estradiol on depression: is estrogen deficiency really necessary?. J Clin Psychiatry 63 (2002) 451-452
87. Zweifel J., and O'Brien W. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22 (1997) 189-212
88. Robinson G. Psychotic and mood disorders associated with the perimenopausal period: epidemiology, aetiology and management. CNS Drugs 15 (2001) 175-184
89. Sherman S. Defining the menopausal transition. Am J Med 118 (2005) 3-7
90. Hlatky M., Boothroyd D., Vittinghoff E., Sharp P., and Whooley M. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287 (2002) 591-597
91. Maclennan A., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4 (2001) 58-74
92. Pearce J., Hawton K., and Blake F. Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Br J Psychiatry 167 (1995) 163-173
93. Burt V., Altshuler L., and Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry 6 (1998) 121-132
94. Schmidt P. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 118 (2005) 54-58
95. Burnam M., Wells K., Leake B., and Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care 26 (1988) 775-789
96. Hays J., Ockene J., Brunner R., Kotchen J., Manson J., Patterson R., Aragaki A., Shumaker S., Brzyski R., LaCroix A., Granek I., and Valanis B. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854
97. Tuunainen A., Langer R., Klauber M., and Kripke D. Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview. Psychiatry Res 103 (2001) 261-270
98. Morrison M., Kallan M., Ten Have T., Katz I., Tweedy K., and Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 55 (2004) 406-412
99. Resnick S., and Henderson V. Hormone therapy and risk of Alzheimer disease: a critical time. Jama 288 (2002) 2170-2172
100. Zandi P., Carlson M., Plassman B., Welsh-Bohmer K., Mayer L., Steffens D., and Breitner J. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288 (2002) 2123-2129
101. Rymer J., and Morris E. Extracts from "Clinical evidence": menopausal symptoms. BMJ 321 (2000) 1516-1519
102. Fitzpatrick L., Pace C., and Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med 9 (2000) 381-387
103. Andreen L., Sundstrom-Poromaa I., Bixo M., Andersson A., Nyberg S., and Backstrom T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30 (2005) 212-224
104. Sherwin B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 72 (1991) 336-343
105. Bjorn I., Bixo M., Nojd K., Nyberg S., and Backstrom T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 183 (2000) 1419-1426
106. Andreen L., Bixo M., Nyberg S., Sundstrom-Poromaa I., and Backstrom T. Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinol 148 (2003) 571-577
107. Whooley M., Grady D., and Cauley J. Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med 15 (2000) 535-541
108. Cathcart C., Jones S., Pumroy C., Peters G., Knox S., and Cheek J. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27 (1993) 277-281
109. Day R., Ganz P., and Costantino J. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst 93 (2001) 1615-1623
110. Nickelsen T., Lufkin E., Riggs B., Cox D., and Crook T. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24 (1999) 115-128
111. Strickler R., Stovall D., Merritt D., Shen W., Wong M., and Silfen S. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 96 (2000) 359-365
112. Jarkova N., Martenyi F., Masanauskaite D., Walls E., Smetnik V., and Pavo I. Mood effect of raloxifene in postmenopausal women. Maturitas 42 (2002) 71-75
113. Vessey M., Fairweather D., Norman-smith B., and Buckley J. A randomized double-blind controlled trial of the value of stilboestrol therapy in pregnancy: long-term follow-up of mothers and their offspring. Br J Obstet Gynaecol 90 (1983) 1007-1017
114. Fried-Cassorla M., Scholl T., Borow L., Strassman H., and Bowers E. Depression and diethylstilbestrol exposure in women. J Reprod Med 32 (1987) 847-850
115. Pillard R., Rosen L., Meyer-Bahlburg H., Weinrich J., Feldman J., Gruen R., and Ehrhardt A. Psychopathology and social functioning in men prenatally exposed to diethylstilbestrol (DES). Psychosom Med 55 (1993) 485-491
116. Titus-Ernstoff L., Perez K., Hatch E., Troisi R., Palmer J., Hartge P., Hyer M., Kaufman R., Adam E., Strohsnitter W., Noller K., Pickett K., and Hoover R. Psychosexual characteristics of men and women exposed prenatally to diethylstilbestrol. Epidemiology 14 (2003) 155-160
117. Cole M., and Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 160 (2003) 1147-1156
118. Pearlstein T., Frank E., Rivera-Tovar A., Thoft J., Jacobs E., and Mieczkowski T. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 20 (1990) 129-134
119. Chuong C., and Burgos D. Medical history in women with premenstrual syndrome. J Psychosom Obstet Gynaecol 16 (1995) 21-27
120. Stowe Z., and Nemeroff C. Women at risk for postpartum-onset major depression. Am J Obstet Gynecol 173 (1995) 639-645
121. Bloch M., Rotenberg N., Koren D., and Klein E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord 88 (2005) 9-18
122. Bloch M., Rotenberg N., Koren D., and Klein E. Risk factors for early postpartum depressive symptoms. Gen Hosp Psychiatry 28 (2006) 3-8
123. O'Hara M., Zekoski E., Philipps L., and Wright E. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 99 (1990) 3-15
124. Nielsen Forman D., Videbech P., Hedegaard M., Dalby J., and Salvig N. Postpartum depression: identification of women at risk. BJOG 107 (2000) 1210-1217
125. Chandraiah S., Richter H., and Holley R. Relationship of reproductive cycle-associated and non-reproductive cycle-associated psychological problems in women. Int J Fertil Womens Med 51 (2006) 33-37
126. Garvey M., Tuason V., Lumry A., and Hoffmann N. Occurrence of depression in the postpartum state. J Affect Disord 5 (1983) 97-101
127. Webster J., Linnane J., Dibley L., and Pritchard M. Improving antenatal recognition of women at risk for postnatal depression. Aust N Z J Obstet Gynaecol 40 (2000) 409-412
128. Parry B., and Newton R. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 25 (2001) S102-S118
129. Steiner M. Female-specific mood disorders. Clin Obstet Gynecol 35 (1992) 599-611
130. Novaes C., Almeida O., and de Melo N. Mental health among perimenopausal women attending a menopause clinic: possible association with premenstrual syndrome? Premenstrual syndrome and psychiatric morbidity at the menopause. Climacteric 1 (1998) 264-270
131. Morse C., Dudley E., Guthrie J., and Dennerstein L. Relationships between premenstrual complaints and perimenopausal experiences. J Psychosom Obstet Gynaecol 19 (1998) 182-191
132. Stewart D., and Boydell K. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 23 (1993) 157-162
133. Richards M., Rubinow D., Daly R., and Schmidt P. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 163 (2006) 133-137
134. Rubinow D., and Schmidt P. The neuroendocrinology of menstrual cycle mood disorders. Ann N Y Acad Sci 771 (1995) 648-659
135. Tiemeier H., Schuit S., den Heijer T., van Meurs J., van Tuijl H., Hofman A., Breteler M., Pols H., and Uitterlinden A. Estrogen receptor alpha gene polymorphisms and anxiety disorder in an elderly population. Mol Psychiatry 10 (2005) 806-807
136. Tsai S., Wang Y., Hong C., and Chiu H. Association study of oestrogen receptor alpha gene polymorphism and suicidal behaviours in major depressive disorder. Psychiatr Genet 13 (2003) 19-22
137. Kendler K., Karkowski L., Corey L., and Neale M. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 155 (1998) 1234-1240
138. Steiner M., Dunn E., and Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord 74 (2003) 67-83
139. Rubinow D., and Schmidt P. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol 27 (2006) 210-216
140. Pardridge W., Moeller T., Mietus L., and Oldendorf W. Blood-brain barrier transport and brain sequestration of steroid hormones. Am J Physiol 239 (1980) E96-E102
141. Speroff L., Glass R., and Kase N. In: Mitchell C. (Ed). Clinical gynecologic endocrinology and infertility (1994), Williams & Wilkins, Baltimore (MD) 59
142. Facchinetti F., Genazzani A., Martignoni E., Fioroni L., Nappi G., and Genazzani A. Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 76 (1993) 1123-1127
143. Pike M., Krailo M., Henderson B., Casagrande J., and Hoel D. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (1983) 767-770
144. Rautalahti M., Albanes D., Virtamo J., Palmgren J., Haukka J., and Heinonen O. Lifetime menstrual activity-indicator of breast cancer risk. Eur J Epidemiol 9 (1993) 17-25
145. Pathak D., Osuch J., and He J. Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 88 (2000) 1230-1238
146. Colditz G., and Frazier A. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 4 (1995) 567-571
147. Nguyen T., Jones G., Sambrook P., White C., Kelly P., and Eisman J. Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab 80 (1995) 2709-2714
148. Fox K., Magaziner J., Sherwin R., Scott J., Plato C., Nevitt M., and Cummings S. Reproductive correlates of bone mass in elderly women. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 8 (1993) 901-908
149. Ancelin M., and Ritchie K. Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des 11 (2005) 4229-4252
150. Frank E., Rucci P., Katon W., Barrett J., Williams J., Oxman T., Sullivan M., and Cornell J. Correlates of remission in primary care patients treated for minor depression. Gen Hosp Psychiatry 24 (2002) 12-19
151. Grigoriadis S., Kennedy S., and Bagby R. A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 23 (2003) 405-407
152. Pinto-Meza A., Usall J., Serrano-Blanco A., Suarez D., and Haro J. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference?. J Affect Disord 93 (2006) 53-60
153. Martenyi F., Dossenbach M., Mraz K., and Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11 (2001) 227-232
154. Kornstein S., Schatzberg A., Thase M., Yonkers K., Mccullough J., Keitner G., Gelenberg A., Davis S., Harrison W., and Keller M. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157 (2000) 1445-1452
155. Quitkin F., Stewart J., McGrath P., Taylor B., Tisminetzky M., Petkova E., Chen Y., Ma G., and Klein D. Are there differences between women's and men's antidepressant responses?. Am J Psychiatry 159 (2002) 1848-1854
156. Cassano P., Soares C., Cusin C., Mascarini A., Cohen L., and Fava M. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom 74 (2005) 362-365
157. Shapira B., Oppenheim G., Zohar J., Segal M., Malach D., and Belmaker R. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 20 (1985) 576-579
158. Schneider L., Small G., Hamilton S., Bystritsky A., Nemeroff C., and Meyers B. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 5 (1997) 97-106
159. Schneider L., Small G., and Clary C. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 9 (2001) 393-399
160. Rasgon N., Altshuler L., Fairbanks L., Dunkin J., Davtyan C., Elman S., and Rapkin A. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 63 (2002) 45-48
161. Morgan M., Cook I., Rapkin A., and Leuchter A. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 66 (2005) 774-780
162. Amsterdam J., Garcia-Espana F., Fawcett J., Quitkin F., Reimherr F., Rosenbaum J., and Beasley C. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 55 (1999) 11-17
163. Rossouw J., Anderson G., Prentice R., LaCroix A., Kooperberg C., Stefanick M., Jackson R., Beresford S., Howard B., Johnson K., Kotchen J., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
164. Nelson H., Humphrey L., Nygren P., Teutsch S., and Allan J. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
165. Farquhar C., Marjoribanks J., Lethaby A., Lamberts Q., and Suckling J. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev (2005) CD004143
166. Skouby S., Al-Azzawi F., Barlow D., Calaf-Alsina Erdogan J., Ertungealp A., Gompel A., Graziottin D., Hudita A., Pines S., Rozenberg G., and Samsioe J. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51 (2005) 8-14
167. Rymer J., Wilson R., and Ballard K. Making decisions about hormone replacement therapy. BMJ 326 (2003) 322-326
168. Ettinger B., Barrett-Connor E., Hoq L., Vader J., and Dubois R. When is it appropriate to prescribe postmenopausal hormone therapy?. Menopause 13 (2006) 404-410
169. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114 (2005) 448-454
170. Stahl S. Sex and psychopharmacology: is natural estrogen a psychotropic drug in women?. Arch Gen Psychiatry 58 (2001) 537-538